{
    "2021-11-02": [
        [
            {
                "time": "",
                "original_text": "【券商聚焦】高盛削上海医药(02607)目标价至4.2%，下调未来三年盈测 机构下调估值",
                "features": {
                    "keywords": [
                        "高盛",
                        "上海医药",
                        "目标价",
                        "下调",
                        "盈测",
                        "估值"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "6家药企前三季度研发投入超过10亿元，创新势头强劲",
                "features": {
                    "keywords": [
                        "药企",
                        "研发投入",
                        "创新",
                        "强劲"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "上海医药Q3财报；AZ又一高管离职；微创医疗再次收购；艾力斯伏美替尼III期达主要终点 董监高成员变化",
                "features": {
                    "keywords": [
                        "上海医药",
                        "Q3财报",
                        "AZ",
                        "高管离职",
                        "微创医疗",
                        "收购",
                        "艾力斯",
                        "伏美替尼",
                        "III期",
                        "董监高变化"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "mixed",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "mixed"
                }
            }
        ]
    ]
}